Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Added to ADT and ARPI in mCSPC With Suboptimal PSA Response
NCT06592924Phase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2025
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Survival at 39 months. Started May 2025; status: recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06592924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592924.